Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes

Annals of Oncology

Volumn 16, Issue 12, 2005, Pages 1921-1927

  Stasi, Roberto ^a   Abruzzese, E ^b   Lanzetta, G ^c   Terzoli, E ^d   Amadori, S ^b  

^a REGINA APOSTOLORUM HOSPITAL   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c INI   (Italy)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Anemia; Darbepoetin alfa; Erythropoietin; Myelodysplastic syndrome; Predictive factors

Indexed keywords

ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER RISK; CONTROLLED STUDY; CORRELATION ANALYSIS; DAILY LIFE ACTIVITY; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; ENERGY; ERYTHEMA; ERYTHROID CELL; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; FUNCTIONAL ASSESSMENT; HUMAN; HYPERTENSION; INJECTION PAIN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; QUESTIONNAIRE; RISK ASSESSMENT; SIDE EFFECT; THROMBOCYTE COUNT; WELLBEING;

AGED; AGED, 80 AND OVER; ANEMIA; APOPTOSIS; BLOOD TRANSFUSION; ERYTHROPOIETIN; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBINS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; QUALITY OF LIFE; RISK FACTORS; TREATMENT OUTCOME;

EID: 28444489284     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi400     Document Type: Article

References (26)

1. Greenberg P, Cox C, LeBeau MM et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
2. Gore S. Classification, treatment goals, and management principles for myelodysplastic syndromes. Cancer Control 2004; 11: 3-6.
3. Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: A meta-analysis of 205 patients from 17 studies. Br J Haematol 1995; 89: 67-71.
4. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Br J Haematol 1998; 103: 1070-1074.
5. Egrie JC, Dwyer E, Browne JK et al. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003; 31: 290-299.
6. Vansteenkiste J, Pirker R, Massuti B et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002; 94: 1211-1220.
7. Hedenus M, Adriansson M, San Miguel J et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study. Br J Haematol 2003; 122: 394-403.
8. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-2302.
9. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
10. Cheson BD, Bennett JM, Kantarjian H et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671-3674.
11. Stasi R, Brunetti M, Bussa S et al. Response to recombinant human erythropoietin in patients with myelodysplastic syndromes. Clin Cancer Res 1997; 3: 733-739.
12. Stasi R, Brunetti M, Terzoli E, Amadori S. Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes. Blood 2002; 99: 1578-1584.
13. Stasi R, Brunetti M, Terzoli E et al. Once-weekly dosing of recombinant human erythropoietin alpha in patients with myelodysplastic syndromes unresponsive to conventional dosing. Ann Oncol 2004; 15: 1684-1690.
14. Coates A, Dillenbeck CF, McNeil DR et al. On the receiving end-II. Linear analogue self-assessment (LASA) in evaluation of aspects of the quality of life of cancer patients receiving therapy. Eur J Cancer Clin Oncol 1983; 19: 1633-1637.
15. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) scale: A new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997; 34: 13-19.
16. Patrick DL, Gagnon DD, Zagari MJ et al. Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer 2003; 39: 335-345.
17. Terpos E, Mougiou A, Kouraklis A et al. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: A phase II trial in 281 patients. Br J Haematol 2002; 118: 174-180.
18. Musto P, Lanza F, Balleari E et al. Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol 2005; 128: 204-209.
19. Greenberg PL. Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment. Leuk Res 1998; 22: 1123-1136.
20. Parker JE, Mufti GJ, Rasool F et al. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 2000; 96: 3932-3938.
21. Wyrwich KW, Bullinger M, Aaronson N et al. Estimating clinically significant differences in quality of life outcomes. Qual Life Res 2005; 14: 285-295.
22. Sloan JA, Cella D, Frost M et al. Assessing clinical significance in measuring oncology patient quality of life: Introduction to the symposium, content overview, and definition of terms. Mayo Clin Proc 2002; 77: 367-370.
23. Cella D, Dobrez D, Glaspy J. Control of cancer-related anemia with erythropoietic agents: A review of evidence for improved quality of life and clinical outcomes. Ann Oncol 2003; 14: 511-519.
24. Spiriti MA, Latagliata R, Niscola P et al. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Ann Hematol 2005; 84: 167-176.
25. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: Significant effects on quality of life. Br J Haematol 2003; 120: 1037-1046.
26. Casadevall N, Durieux P, Dubois S et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: A randomized, controlled trial. Blood 2004; 104: 321-327.